BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 32023748)

  • 1. [Epidemiological analysis of cytogenetic abnormalities in patients with newly-diagnosed multiple myeloma: a multi-center retrospective study].
    Yuan RF; Dong YJ; Li CR; Huang WR; Zhang LM; Zhu Q; Xu L; Xu YJ; Xu Q; Gao GX; Jin FY
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jan; 41(1):10-15. PubMed ID: 32023748
    [No Abstract]   [Full Text] [Related]  

  • 2. [Prognostic analysis of 182 newly diagnosed multiple myeloma patients with high risk cytogenetic abnormalities].
    Liu XL; Bai J; Fan HQ; Yang YP; Yue TT; Zhang Y; Yang PY; Gao SJ; Li W; Jin FY
    Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):644-649. PubMed ID: 31495130
    [No Abstract]   [Full Text] [Related]  

  • 3. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].
    Liu XL; Yang YP; Bai J; Yue TT; Yang PY; Zhang Y; Fan HQ; Li W; Jin FY
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):912-917. PubMed ID: 31856439
    [No Abstract]   [Full Text] [Related]  

  • 4. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization.
    Chen L; Li J; Xu W; Qiu H; Zhu Y; Zhang Y; Duan L; Qian S; Lu H
    Exp Oncol; 2007 Jun; 29(2):116-20. PubMed ID: 17704743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Cytogenetic abnormalities and prognosis of 532 patients with multiple myeloma].
    Wu H; Zhang H; He HY; Jiang H; Zhao YY; An R; He J; Li R; Lu J; Hou J
    Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):739-743. PubMed ID: 29081188
    [No Abstract]   [Full Text] [Related]  

  • 6. [Comparative study of genetic aberrations in human multiple myeloma cell lines and newly diagnosed MM by fluorescence in situ hybridization].
    An G; Xie ZQ; Li CH; Li Q; Yi SH; Qiu LG
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Dec; 18(6):1505-10. PubMed ID: 21176360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Observation on frequency & clinico-pathological significance of various cytogenetic risk groups in multiple myeloma: an experience from India.
    Kadam Amare PS; Jain H; Nikalje S; Sengar M; Menon H; Inamdar N; Subramanian PG; Gujral S; Shet T; Epari S; Nair R
    Indian J Med Res; 2016 Oct; 144(4):536-543. PubMed ID: 28256461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma.
    Uryu H; Mishima Y; Ishihara Y; Shirouchi Y; Yamauchi N; Hirano M; Hirano K; Teramoto Y; Yoshida K; Maruyama D
    J Clin Exp Hematop; 2024; 64(1):10-20. PubMed ID: 38538316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?
    Leiba M; Duek A; Amariglio N; Avigdor A; Benyamini N; Hardan I; Zilbershats I; Ganzel C; Shevetz O; Novikov I; Cohen Y; Ishoev G; Rozic G; Nagler A; Trakhtenbrot L
    Genes Chromosomes Cancer; 2016 Sep; 55(9):710-8. PubMed ID: 27152944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice.
    Mizuguchi M; Okamoto Y; Yagi H; Kagawa K; Sekimoto E; Shibata H; Shigekiyo T; Ozaki S
    Int J Hematol; 2023 May; 117(5):718-728. PubMed ID: 36692689
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor.
    Schavgoulidze A; Talbot A; Perrot A; Cazaubiel T; Leleu X; Manier S; Buisson L; Mahéo S; Do Souto Ferreira L; Pavageau L; Hulin C; Marolleau JP; Voillat L; Belhadj K; Divoux M; Slama B; Brechignac S; Macro M; Stoppa AM; Sanhes L; Orsini-Piocelle F; Fontan J; Chretien ML; Demarquette H; Mohty M; Avet-Loiseau H; Corre J
    Blood; 2023 Mar; 141(11):1308-1315. PubMed ID: 36375118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Impact of Cytogenetic Abnormalities in Multiple Myeloma: A Retrospective Analysis of 229 Patients.
    Jian Y; Chen X; Zhou H; Zhu W; Liu N; Geng C; Chen W
    Medicine (Baltimore); 2016 May; 95(19):e3521. PubMed ID: 27175647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma.
    Kaufmann H; Krömer E; Nösslinger T; Weltermann A; Ackermann J; Reisner R; Bernhart M; Drach J
    Eur J Haematol; 2003 Sep; 71(3):179-83. PubMed ID: 12930318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic power of abnormal cytogenetics for multiple myeloma: a multicenter study in China.
    Lai YY; Huang XJ; Cai Z; Cao XS; Chen FP; Chen XQ; Chen BA; Fang MY; Feng JF; Fu WL; Guo HY; Hou M; Hou J; Hu Y; Hu XT; Hu XM; Huang LQ; Jin J; Li JY; Li J; Li W; Liang YM; Liu T; Liu QF; Liu YH; Mao P; Ouyang J; Qiu LG; Qiu L; Shao CK; Shi B; Song YP; Sun ZM; Wang QS; Wang C; Wang JM; Wang YS; Wang Z; Wu JB; Wu YX; Xia RX; Xue YQ; Yang BZ; Yang G; Yang ZL; Yu L; Yuan Z; Zhang S; Zhang Y; Zhao HG; Zhao L; Zhou DB; Zou SH; Zhu YF
    Chin Med J (Engl); 2012 Aug; 125(15):2663-70. PubMed ID: 22931972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of the Cytogenetic Aberrations in Multiple Myeloma by Using Microrray Comparative Genomic Hybridization].
    Wang YF; Wang H; Xi LY; Zhang ZH; Wang J; Dong F; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Oct; 26(5):1389-1395. PubMed ID: 30295256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma.
    Cui J; Lv R; Yu T; Yan W; Xu J; Fan H; Li L; Liu Y; Du C; Deng S; Sui W; Xu Y; Yi S; Zou D; Qiu L; An G
    Haematologica; 2024 Feb; 109(2):591-603. PubMed ID: 37534514
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Influence of the number of high-risk cytogenetic abnormalities on the clinical characteristics and prognosis in 360 patients with newly diagnosed multiple myeloma].
    Chen Z; Xia Y; Guo R; Zhang R; Qiu HR; Jin YY; Li JY; Chen LJ
    Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):408-413. PubMed ID: 35680599
    [No Abstract]   [Full Text] [Related]  

  • 18. Presentation and Impact of Double and Triple hit Cytogenetics in Patients With Multiple Myeloma in the Real World.
    Singh C; Panakkal V; Sreedharanunni S; Jandial A; Jain A; Lad D; Prakash G; Khadwal A; Malhotra P
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e685-e690. PubMed ID: 35422411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China.
    Shen M; Yang G; Li X; Geng C; Huang Z; Chen W
    Leuk Lymphoma; 2021 Dec; 62(12):2992-3001. PubMed ID: 34219587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concepts of Double Hit and Triple Hit Disease in Multiple Myeloma, Entity and Prognostic Significance.
    Baysal M; Demirci U; Umit E; Kirkizlar HO; Atli EI; Gurkan H; Gulsaran SK; Bas V; Mail C; Demir AM
    Sci Rep; 2020 Apr; 10(1):5991. PubMed ID: 32249811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.